Cowen and Company upgraded shares of Achaogen Inc. (NASDAQ:AKAO) from a market perform rating to an outperform rating in a research report released on Monday morning.

“AKAO moved up Plazomicin (Plz) pivotal Ph3 EPIC cUTI top-line and CARE trial data.”,” Cowen and Company’s analyst wrote.

A number of other research analysts have also recently commented on the company. Zacks Investment Research cut Achaogen from a buy rating to a hold rating in a research note on Thursday, August 11th. SunTrust Banks Inc. restated a buy rating and set a $10.00 price target on shares of Achaogen in a research note on Monday, September 26th. Wedbush restated an outperform rating and set a $10.00 price target on shares of Achaogen in a research note on Tuesday, September 27th. Needham & Company LLC restated a hold rating on shares of Achaogen in a research note on Tuesday, August 9th. Finally, Aegis initiated coverage on Achaogen in a research note on Wednesday, November 2nd. They set a buy rating and a $10.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $8.63.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Shares of Achaogen (NASDAQ:AKAO) opened at 5.08 on Monday. Achaogen has a 52-week low of $2.59 and a 52-week high of $6.18. The firm’s market cap is $139.45 million. The stock has a 50 day moving average price of $4.88 and a 200-day moving average price of $4.17.

Achaogen (NASDAQ:AKAO) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.20. Achaogen had a negative return on equity of 143.44% and a negative net margin of 147.80%. The firm had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $8.72 million. During the same period in the prior year, the firm posted ($0.48) earnings per share. The firm’s quarterly revenue was up 258.3% on a year-over-year basis. On average, equities analysts anticipate that Achaogen will post ($2.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this story on another domain, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be read at http://www.financial-market-news.com/achaogen-inc-akao-upgraded-to-outperform-at-cowen-and-company/1208206/.

Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp raised its stake in Achaogen by 52.6% in the third quarter. Northern Trust Corp now owns 23,346 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 8,046 shares in the last quarter. ICONIQ Capital LLC raised its stake in Achaogen by 100.3% in the second quarter. ICONIQ Capital LLC now owns 28,629 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 14,333 shares in the last quarter. Redmile Group LLC bought a new stake in Achaogen during the third quarter worth $155,000. A.R.T. Advisors LLC bought a new stake in Achaogen during the second quarter worth $142,000. Finally, Eagle Global Advisors LLC raised its stake in Achaogen by 55.4% in the second quarter. Eagle Global Advisors LLC now owns 38,749 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 13,812 shares in the last quarter. 54.69% of the stock is currently owned by institutional investors and hedge funds.

Achaogen Company Profile

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

5 Day Chart for NASDAQ:AKAO

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.